Web Exclusives

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment.

A recently released report indicates that low-dose computed tomography targeted screening for lung cancer confers patient health and public health benefits.

A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials.

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer.

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer.

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma.

Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study.

A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers.

Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response.

Recently released analysis of ¹⁸F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.

NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.

Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after ¹⁸F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.

Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.

Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.

The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.

Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.

Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.

Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.

Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.

In recently released study results of the phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate across all trial subgroups.

Lung cancer incidence rates have declined due to a decrease in risk factors and improved screening and treatment.

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment.

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations.

Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy.

Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article.

A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC.

A retrospective analysis demonstrated a 10-point difference in receipt of NGS testing between white and black patients with NSCLC.

Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations.

A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.

Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRAS^G12C-mutated NSCLC subtypes.